Targeting PINK1 using phytochemicals: exploring molecular insights into Parkinson's disease therapeutics.

Parkinson's disease (PD) is one of the most commonly affecting neurodegenerative disorder prevalent in our society. The inherited autosomal recessive PD/parkinsonism occurs due to mutations in six genes including, the gene for PTEN (phosphatase and tensin homologue)-induced putative kinase1 (PINK1). The pathophysiology and development of disorders associated with the mitochondria occur simultaneously with the dysregulation of PINK1. The activation/regulation of PINK1 through autophagy regulators can reduce PD condition. This study focused on exploring the possibility of 2062 phytochemicals as autophagy regulators. In silico docking and simulation studies are performed to identify their binding with the PINK1. Our studies highlight the phytochemicals like Proanthocyanidin A-6, Withanolide Q, and pseudo-ginsenoside F11 that showed higher binding energy and stable interactions during the course of simulation. This study opens avenues for testing these compounds as positive modulators of PINK1 kinase activity using in vitro and in vivo methods and use of these compounds as phytotherapeutic for the treatment of PD.